Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab for Prevention of GVHD After Stem Cell Transplantation
NCT07808112Phase 2Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2026
- Primary completion
- Nov 2031
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in graft-versus-host disease (GVHD), sponsored by Medical College of Wisconsin. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
axatilimab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07808112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808112.